PMID: 10905766Jul 25, 2000

Autologous hematopoietic cell transplantation in Hodgkin's disease

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
L J Johnston, Sandra J Horning

Abstract

The use of HDT and AHCT in Hodgkin's disease patients with early relapsed and refractory disease is supported by historical comparisons. In regard to the late relapsed patient or the newly diagnosed high-risk patient, the role AHCT plays would ideally be answered by well-controlled phase 3 trials. A surrogate approach would be the comparison of AHCT data with well-matched historical controls. It is important, however, to be mindful of the changes that have occur red in the therapy of the newly diagnosed and relapsed HD patient (ABVD replacing MOPP regimens) and the impact these changes may or may not have on nonrelapse mortality in the autografted and nonautografted setting. In addition, the incorporation of consistent prognostic factors in any trial design may identify groups of relapsed or refractory and high-risk HD patients who may or may not gain benefit from HDT. The most effective and efficient route to answering these treatment questions is enrollment of patients in well-controlled and well-designed clinical trials.

References

Dec 18, 2007·Bone Marrow Transplantation·M B Bradley, M S Cairo
Nov 13, 2014·Expert Opinion on Therapeutic Targets·Elena Herrera-Carrillo, Ben Berkhout
Aug 20, 2008·British Journal of Haematology·Karl S PeggsAnna Sureda
Dec 18, 2008·British Journal of Haematology·Jessica HochbergM S Cairo
Dec 23, 2011·British Journal of Haematology·Kara M Kelly
Oct 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M S CairoJohn Pagel
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard E HarrisM S Cairo
Jul 21, 2015·Viruses·Elena Herrera-Carrillo, Ben Berkhout

Related Concepts

Actuarial Analysis
Survival Analysis
Cross-Over Studies
Antineoplastic Chemotherapy Protocols
Combined Modality Therapy
Progression-Free Survival
Remission Induction
Clinical Trials
Hemopoietic Stem Cell Transplant
Transplantation, Autologous

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.